Literature DB >> 29419447

Challenges and Advances in Targeting Remission in Axial Spondyloarthritis.

Xenofon Baraliakos1, Francis Berenbaum2, Ennio Giulio Favalli3, Ignazio Olivieri4, Benedikt Ostendorf5, Denis Poddubnyy6, Kurt DE Vlam7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29419447     DOI： 10.3899/jrheum.170222

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  6 in total

Review 1.  Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions.

Authors:  Jean W Liew; Maureen Dubreuil
Journal:  Rheum Dis Clin North Am       Date:  2020-05       Impact factor: 2.670

2.  Treating to Target in Clinical Practice: The Results of a Questionnaire Completed by Greek Rheumatologists.

Authors:  Theofilos-Diamantis Karatsourakis; Xenofon Baraliakos
Journal:  Mediterr J Rheumatol       Date:  2020-05-25

3.  Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.

Authors:  Jun Won Park; Hyoun-Ah Kim; Kichul Shin; Yong-Beom Park; Tae-Hwan Kim; Yeong Wook Song; Eun Young Lee
Journal:  Arthritis Res Ther       Date:  2019-07-04       Impact factor: 5.156

4.  Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.

Authors:  Xenofon Baraliakos; Filip Van den Bosch; Pedro M Machado; Lianne S Gensler; Helena Marzo-Ortega; Bintu Sherif; Erhard Quebe-Fehling; Brian Porter; Corine Gaillez; Atul Deodhar
Journal:  Rheumatol Ther       Date:  2020-12-22

5.  Treat-to-Target in Axial Spondyloarthritis: Are we there yet?

Authors:  Krystel Aouad; Bassel El-Zorkany
Journal:  Mediterr J Rheumatol       Date:  2022-04-15

6.  Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.

Authors:  Denis Poddubnyy; Ludwig Hammel; Marvin Heyne; Justyna Veit; Claudia Jentzsch; Xenofon Baraliakos
Journal:  BMJ Open       Date:  2020-09-30       Impact factor: 2.692
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.